- Home
- CEE vs MCRB Comparison
CEE vs MCRB Comparison
Compare CEE & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEE | MCRB |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 139.7M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CEE | MCRB |
|---|---|---|
| Price | $17.49 | $8.94 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 23.5K | ★ 41.2K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.20 | $0.36 |
| 52 Week High | $19.98 | $29.98 |
Technical Indicators
Market Signals| Indicator | CEE | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 38.36 | 44.55 |
| Support Level | $16.97 | $7.55 |
| Resistance Level | $18.35 | $9.53 |
| Average True Range (ATR) | 0.69 | 0.64 |
| MACD | -0.06 | 0.20 |
| Stochastic Oscillator | 12.10 | 58.45 |
Price Performance
Historical ComparisonAbout CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.